Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
doi: 10.3389/fendo.2025.1483199 Received 19 August 2024 Accepted 10 January 2025 Published 17 February 2025 Volume 16 - 2025 Edited by Brenda Kohn, New York University, United States Reviewed by Ekaterina Koledova, Merck, Germany Torben Laursen, Aarhus University Hospital, Denmark Updates Copyright 2025 Levshtein, Sharkia, Shimshi-Barash, Almagor, Albertsson-Wikland, Hochberg, Pillar and German
Unlike PDE-5 inhibitors, PT-141 does not depend primarily on peripheral blood flow modulation
"Special Characterist Page 108 and 109: Danet AF, David V, and David I
Considerations include: Lower initial dosing where appropriate Close monitoring for gastrointestinal intolerance Assessment of comorbidities and polypharmacy risks 15.2 Administration to Pregnant Women Human data remain limited
US$ 21.97
US$ 27.83
US$ 20.79
US$ 28.78
US$ 21.04
US$ 21.80
